Polycythemia can qualify as a disability under both Social Security Administration (SSA) and Department of Veterans Affairs (VA) programs, but approval depends on the severity of your condition, the treatment you require, and how much it limits your ability to work. There is no automatic “yes” here. The path to approval differs significantly between the two systems, and many people with polycythemia need to build a case around their functional limitations rather than relying on the diagnosis alone.
How the VA Rates Polycythemia
The VA has a specific diagnostic code (7704) for polycythemia vera with four rating levels tied directly to how aggressively you need treatment. This is the more straightforward of the two systems because the criteria are concrete and treatment-based.
- 10% rating: You need blood removal (phlebotomy) three or fewer times per year, or you take biologic therapy intermittently to keep blood values in the normal range.
- 30% rating: You need phlebotomy four to five times per year, or you take continuous medication to keep platelet or white blood cell counts below specific thresholds.
- 60% rating: You need phlebotomy six or more times per year, or you take molecularly targeted therapy to control red blood cell counts.
- 100% rating: You need a stem cell transplant or chemotherapy to manage your symptom burden.
The key detail: the VA rates based on the intensity of your current treatment, not just your diagnosis. If your condition worsens and your treatment escalates, you can request a higher rating. Veterans who also develop complications like blood clots or progression to a more advanced bone marrow disease may receive additional ratings for those secondary conditions.
How Social Security Evaluates Polycythemia
The SSA process is less direct. There is no specific Blue Book listing for polycythemia vera by name. The closest listing is 7.10, which covers bone marrow failure disorders including myelofibrosis, a condition that polycythemia vera can progress into over time. To meet Listing 7.10 automatically, you would need complications requiring at least three hospitalizations in a 12-month period, each lasting at least 48 hours and spaced at least 30 days apart.
Most people with polycythemia vera won’t meet that threshold, especially if their condition is managed in outpatient settings. That doesn’t mean you can’t get approved. It means the SSA will evaluate your case through what’s called a residual functional capacity assessment. This is where the agency looks at what you can still do physically and mentally despite your condition, then determines whether any jobs exist that you could realistically perform.
This is where documenting your daily limitations becomes critical. The SSA will consider fatigue, cognitive difficulties, how often you miss work for treatment, and whether complications like blood clots have caused lasting damage.
Why Polycythemia Limits Work Ability
The diagnosis itself doesn’t always sound disabling to someone unfamiliar with it, but the day-to-day reality can be severe. Polycythemia vera carries a blood clot rate of about 2.6% per year after diagnosis. Arterial clots, which can cause strokes and heart attacks, occur at roughly 1.6% per year. In a study of 1,545 patients followed for a median of nearly seven years, 18% developed a clot during follow-up, and those patients had double the 10-year mortality rate compared to those who remained clot-free (40% versus 20%). A stroke or heart attack at any point in the disease can create permanent physical or cognitive limitations that independently qualify for disability.
Even without a major clot event, the disease progresses. About 9% of patients in that same study developed bone marrow scarring (post-PV myelofibrosis), and 3% progressed to a blast phase resembling acute leukemia. The probability of remaining event-free at 10 years after diagnosis was only 60%.
How Treatment Itself Affects Function
Phlebotomy, the most common first-line treatment, sounds simple: a large-bore needle removes blood to lower red blood cell counts. But research published in the Journal of Clinical Medicine found that even in patients classified as “low risk,” phlebotomy causes measurable declines in cognitive function, emotional well-being, and social functioning. The procedure deliberately induces iron deficiency to slow red blood cell production, and that iron deficiency brings its own problems: persistent fatigue, brain fog, restless legs, and unusual cravings. Patients also deal with the practical burden of traveling to treatment centers, recovery time after each session, and the pain of repeated large-needle insertions.
Fatigue is the symptom most likely to interfere with employment. It reduces both quality of life and work productivity, and it tends to worsen as phlebotomy sessions increase. When patients need three or four sessions per year, their blood counts between treatments become unstable, making symptom control inconsistent.
For patients who move beyond phlebotomy to medications like hydroxyurea, the side effect profile adds another layer. Common effects include nausea, diarrhea, mouth sores, dizziness, and hair loss. More seriously, hydroxyurea suppresses bone marrow function broadly, which can increase infection and bleeding risk. It also carries a long-term association with secondary cancers. These side effects can make sustained full-time employment difficult, particularly in physically demanding or infection-prone work environments.
Building a Stronger Disability Claim
Whether you’re filing with the VA or SSA, the strength of your claim depends on medical documentation. For polycythemia vera, diagnosis typically requires blood tests showing elevated hemoglobin (above 18.5 g/dL in men or 16.5 g/dL in women) plus a positive test for the JAK2 gene mutation, which is present in over 98% of polycythemia vera cases. A low erythropoietin level and bone marrow biopsy results provide additional diagnostic evidence.
Beyond confirming the diagnosis, you need records that show how the disease and its treatment affect your ability to function. This means documenting every phlebotomy session, every medication change, every emergency visit for clot symptoms, and every appointment where you report fatigue, cognitive problems, or other limitations. If you’ve had to reduce your work hours, change roles, or stop working entirely, notes from your hematologist connecting those changes to your condition carry significant weight.
For SSA claims specifically, a detailed statement from your treating physician about what you can and cannot do physically and mentally is one of the most influential pieces of evidence. This should address how long you can sit, stand, walk, and concentrate, how often you need to rest, and how many days per month your symptoms would likely cause you to miss work.
Secondary Polycythemia Is Treated Differently
Everything above applies primarily to polycythemia vera, the bone marrow cancer. Secondary polycythemia, where red blood cell counts rise in response to another condition like chronic lung disease, sleep apnea, or living at high altitude, is evaluated differently. The VA does not have a separate rating code for secondary polycythemia. Instead, the underlying cause gets rated, and any additional functional limitations from the elevated blood counts may factor into the overall assessment. For SSA purposes, secondary polycythemia would similarly be evaluated based on the root condition and its combined effect on your work capacity.
If you have secondary polycythemia, your disability claim will generally be built around the primary diagnosis rather than the blood count elevation itself. Treating the underlying cause, such as using a breathing machine for sleep apnea, often resolves or improves the polycythemia.